News

Prim. Pavel Jindra: Biosimilars are an accessible and effective treatment modality in hematooncology

24. 3. 2022 Source: Oncological Treatment

“Based on our experience so far, biosimilars represent an effective and safe alternative to original molecules. We are not afraid to use them anywhere in approved indications, and we are not afraid of switching either. Biosimilars are a significant step towards greater accessibility of hematooncological treatment for a wide group of patients,” states the head of the Hematology-Oncology Department of FN Plzeň, MUDr. Pavel Jindra, Ph.D., in our current interview.

You can confirm or exclude ATTRv amyloidosis through genetic testing

16. 3. 2022 Source: Rare Diseases

Combined Hormonal Contraception in the Treatment of Dysmenorrhea

Dysmenorrhea troubles many women of reproductive age and can deteriorate their quality of life, making it important for doctors to offer suitable therapy. We summarize the findings of research on the…

15. 3. 2022 Source: Oral Contraception

Parenteral Nutrition in Oncological Patients in Current ESPEN Recommendations

The current guidelines of the European Society for Clinical Nutrition and Metabolism (ESPEN) address nutritional care in oncological patients −⁠ current knowledge is summarized in a total of 43…

15. 3. 2022 Source: Parenteral Nutrition

Rakovina_pacientka s šátkem_ lékař vysvětluje_ diagnóza

Parenteral Nutrition as Part of Cancer Patient Treatment

Malnutrition represents a potentially serious complication for cancer patients. If it is not possible to meet the nutritional demands of the body through the enteral route, parenteral nutrition must…

15. 3. 2022 Source: Parenteral Nutrition

Why can probiotics and vitamin D significantly affect human health?

Vitamin D deficiency is the most common hypovitaminosis in developed countries. It is largely related to a lack of outdoor activity. Additionally, the typical Western diet does not support a healthy…

15. 3. 2022 Source: GI, colic and microbiome

Results of Knee and Hip Joint Arthroplasty in Hemophiliacs

Total endoprosthesis implantation represents an effective solution for the terminal stages of joint degeneration in hemophiliacs. However, compared to the general population, this group of patients…

15. 3. 2022 Source: Hemophilia with Movement

What Shape and Size of Tablets Do Our Patients Prefer?

The size and shape of tablets can affect patients' compliance with treatment. The following article provides an overview of conclusions from two foreign studies focused on influencing the difficulty…

14. 3. 2022 Source: Cardiovascular Continuum

How many heart failure patients do not take adequate doses of beta-blockers even though they could?

A British study published last year investigated the proportion of heart failure patients with reduced ejection fraction (HFrEF) who do not take an adequate dose of beta-blockers (BB), despite having…

14. 3. 2022 Source: Cardiovascular Continuum

Dust mite allergy is a significant risk factor (not only) for the development of asthma

Dust mite allergy is the most common cause of year-round allergic rhinitis in our country. Its prevalence is increasing every year, but non-specific manifestations also cause its underdiagnosis.…

14. 3. 2022 Source: Dust Mite Allergy

Efficacy of Sublingual Immunotherapy in Patients with Atopic Dermatitis Sensitized to Dust Mite Allergens

In patients with atopic dermatitis (AD), sensitization to house dust mite allergens is common. According to studies, subcutaneous immunotherapy (SCIT) represents an effective adjunct therapy. The…

11. 3. 2022 Source: Dust Mite Allergy

Weight-Based Enoxaparin Dosing vs. Standard Dosing in Trauma Patients

Thromboembolic disease is a common comorbidity in adult trauma patients, thus making routine thromboprophylaxis appropriate for these patients, most often in the form of low-molecular-weight heparins…

9. 3. 2022 Source: Thromboprophylaxis

EMA Approved Empagliflozin for the Treatment of Heart Failure Regardless of Left Ventricular Ejection Fraction

Prague, March 8, 2022 –⁠ Hundreds of thousands of patients in the Czech Republic can soon look forward to a treatment that may positively influence the progression of their disease. The European…

8. 3. 2022 Source: Heart Failure

Fexofenadine –⁠ Non-Sedative and Immunomodulatory Antihistamine in the Treatment of Allergic Symptoms

One of the biggest limitations of traditional antihistamines is the sedative effect on the central nervous system. Newer antihistamines do not cause sedation, are not associated with serious side…

3. 3. 2022 Source: Viral infections

Does gliflozin treatment for heart failure have greater benefits in diabetics?

Inhibitors of glucose reabsorption in the proximal tubule are represented on the domestic market by several molecules including empagliflozin. The EMPEROR-Reduced study monitored the impact of…

3. 3. 2022 Source: Heart Failure

1 … 58 59 60 61 62 … 115

Back Filter by speciality

Remove filters

Popular this week